Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aminocamptothecin in Advanced Cutaneous T-Cell Lymphoma
NCT00002635Phase 2Completed
- Sponsor
- Yale University
- Start
- May 1995
- Primary completion
- Apr 2000
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 9-aminocamptothecin in cutaneous T-cell lymphoma (CTCL), sponsored by Yale University. Primary endpoint: Antitumor activity. Started May 1995; status: completed.
02
Drugs
9-aminocamptothecin
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT00002635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002635.